Mice lacking AMP-activated kinase (AMPK) subunits β1 or β2 have low bone mass, while AICAR acts AMPK-independently to increase osteoclast formation
Julian M.W. Quinn(Cancer Institute of New South Wales), Bryce J. W. van Denderen(St Vincent's Hospital Melbourne), Matthew T. Gillespie(Hudson Institute of Medical Research), H. Saleh(The University of Melbourne), John W. Scott(Seattle University), Bruce E. Kemp(The University of Melbourne), Shanna Tam(St Vincent's Hospital Melbourne), Natalie A. Sims(The University of Melbourne), Emma C. Walker(Washington University in St. Louis), Narelle E. McGregor(St. Vincent's Medical Center), Ingrid J. Poulton(St Vincents Institute of Medical Research)
Cited by 2
Related Papers
Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families
|Endocrine Reviews|1999|2.3k
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
|Journal of Clinical Investigation|1999|1.7k
Interleukin-6 Increases Insulin-Stimulated Glucose Disposal in Humans and Glucose Uptake and Fatty Acid Oxidation In Vitro via AMP-Activated Protein Kinase
|Diabetes|2006|893
AMP‐activated protein kinase phosphorylation of endothelial NO synthase
|FEBS Letters|1999|832
Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1
|Endocrinology|1999|536